Lynch syndrome is an inherited predisposition to several types of cancer. In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel (TEST ID: LYNCP) establishes a diagnosis of Lynch syndrome, to guide targeted cancer surveillance.

"We can tailor screening recommendations to the individual's specific cancer risk profile," Dr. Shen says. "Knowledge of genetic cancer risk can empower individuals to make informed decisions about their health care and lifestyle choices."

Lynch syndrome confers a particularly high risk for colon and endometrial cancers. The National Comprehensive Cancer Network recommends testing for Lynch syndrome for patients under age 50 who have a diagnosis of either of those cancers. Mayo Clinic Laboratories' next generation sequencing panel tests whole blood samples for variants in five genes associated with Lynch syndrome.

Some of those genes pose particular challenges. Mayo Clinic Laboratories adds supplemental assays to cover additional variants and genomics regions. Several other tests, including a unique test to identify hypermethylation, are available if the suspicion of Lynch syndrome isn't clear.

"Our commitment to providing complete and accurate results motivates us to go beyond the standard laboratory testing process," Dr. Shen says. "Performing all these tests in the same laboratory allows us to integrate the results, to provide the most comprehensive testing and interpretation for patients."

Listen to learn more about Mayo Clinic Laboratories' Lynch syndrome panel.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

LYNCP   | Lynch Syndrome Panel, Varies

Lynch Syndrome testing algorithm

Additional testing

CRCGP   | Hereditary Gastrointestinal Cancer Panel, Varies

FMTT   | Familial Mutation, Targeted Testing, Varies

MLHPB   | MLH1 Hypermethylation Analysis, Blood

The latest

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

April 30, 2024

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

April 16, 2024

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

View MoreView Less